AGP Picks
View all

The Boston Examiner: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Boston Examiner.

Press releases published on November 4, 2026

Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LeMaitre Q3 2026 Financial Results
Rapid7 Announces Third Quarter 2026 Financial Results
Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates
AMSC Reports Second Quarter Fiscal Year 2026 Financial Results and Business Outlook
Great Elm Group Reports Fiscal 2027 First Quarter Financial Results
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Celldex to Present at Upcoming Investor Conferences
Definitive Healthcare announces executive appointments to bolster AI-powered initiatives across the company
Hydrogen Internal Combustion Engine (H2ICE) Market to Reach $2.3 Billion by 2031, Driven by Government Mandates and Surging Hydrogen Infrastructure Investment
Tessera Therapeutics to Present New Preclinical Data Supporting its In Vivo Sickle Cell Disease Program and In Vivo CAR-T Applications at the 68th American Society of Hematology Annual Meeting
Congress Must Make 2027 America’s Anti-Corruption Year
Tycho.AI Unveils Horizon: The Agile Autonomy Stack and Application Suite Delivering Full Mission Autonomy Across Denied and Contested Domains
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting
Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting
Report: 86% of Insurance Executives in Canada Believe AI Will Strengthen Customer Trust, Only 33% of Policyholders Agree
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
Solu Therapeutics to Present Initial Phase 1 Results of STX-0712 and New Preclinical Data on STX-0640 in Two Oral Presentations at the 2026 ASH Annual Meeting

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The Boston Examiner

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.